Nutriband Inc（NTRB）股票分析

AI 分析 of Nutriband Inc (NTRB)

持有

Nutriband Inc (NTRB) is currently trading at $6.41, which is 56.5% of its 52-week range, indicating it is positioned in the middle of its historical price range. The RSI is at 55.845, suggesting the stock is neither overbought nor oversold. However, the forward P/E ratio is extremely high at 370.37, indicating that the stock may be overvalued based on future earnings expectations. Additionally, the recent earnings report showed an EPS of -0.07, reflecting ongoing losses. While the stock has seen a year-to-date increase of 44.70%, the significant net losses and high valuation metrics present risks. Therefore, it is advisable to hold rather than buy at this time, as the potential for further gains is tempered by these financial concerns.

估值指标

Nutriband Inc（NTRB）当前预期市盈率为 370.37，5 年平均预期市盈率为 54.60。

预期市盈率

高估

5 年均值 P/E

54.60

当前P/E

370.37

高估

213.76

低估

-104.56

预期 EV/EBITDA

高估

5 年均值 EV/EBITDA

-6.97

当前EV/EBITDA

0.00

高估

-0.21

低估

-13.74

预期市销率

低估

5 年均值 P/S

10.57

当前P/S

0.00

高估

17.77

低估

3.37

Alphio AI 对 NTRB 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重（25 / 50 / 25），不构成保证。

乐

乐观

乐观 · 25%NTRB

$8.90

情景价格

基

基准

基准 · 50%NTRB

$6.95

情景价格

悲

悲观

悲观 · 25%NTRB

$4.05

情景价格

NTRB 常见问题 —— 由 Alphio AI 解答

Nutriband Inc. is engaged in the development of a portfolio of transdermal pharmaceutical products. Its development pipeline consists of transdermal products that are based on proprietary AVERSA abuse-deterrent transdermal technology. Its lead product under development is AVERSA Fentanyl, an abuse deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with its AVERSA abuse deterrent transdermal technology to reduce the abuse and misuse of fentanyl patches. Its development pipeline also includes AVERSA Buprenorphine and AVERSA Methylphenidate. It is developing a portfolio of transdermal pharmaceutical products to deliver already approved drugs or biologics that are typically delivered by injection but with the potential to improve compliance and therapeutic outcomes through transdermal delivery. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. It operates in the Healthcare sector (ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUP industry).

Nutriband Inc (NTRB) is currently trading at $6.41, which is 56.5% of its 52-week range, indicating it is positioned in the middle of its historical price range. The RSI is at 55.845, suggesting the stock is neither overbought nor oversold. However, the forward P/E ratio is extremely high at 370.37, indicating that the stock may be overvalued based on future earnings expectations. Additionally, the recent earnings report showed an EPS of -0.07, reflecting ongoing losses. While the stock has seen a year-to-date increase of 44.70%, the significant net losses and high valuation metrics present risks. Therefore, it is advisable to hold rather than buy at this time, as the potential for further gains is tempered by these financial concerns.